-
-
-
-
-
-
-
Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
-
-
-
-
-
-
-
Clovis Oncology (CLVS) Misses Q3 EPS by 8c; Reports $171.9M in Cash and Cash Equivalents
-
-
-
-
-
-
-
Clovis Oncology (CLVS) Tops Q1 EPS by 8c
-
-
-
-
-
-
-
Clovis Oncology (CLVS) Announces Preliminary Product Revenues for Q4
-
-
-
-
-
-
-
Clovis Oncology (CLVS) Misses Q1 EPS by 12c
-
-
-
-
-
-
-
Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24
-
-
-
-
-
-
-
Clovis Oncology (CLVS) Reports Acquisition of Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

